6-K filed Jul 30, 2026 at 08:15 ET
Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year post-FDA approval, with US$103M cash at quarter end. Operational milestones include commencement of the adult SR-aGvHD label extension trial, IND clearance for Duchenne muscular dystrophy, and achievement of the 300-patient enrollment target in the pivotal Phase 3 chronic low back pain trial. The company also received a BLA filing number for rexlemestrocel-L in LVAD patients and acquired a CAR technology license.